ArticlePharmacoEconomics - open2026
Incremental Disease Burden (Healthcare Costs and Resources) of Duchenne Muscular Dystrophy in the US: A Matched Cohort Analysis.
Article in PharmacoEconomics - open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuchenne muscular dystrophy (DMD) is a rare genetic condition that causes progressive muscle weakness and reduced life expectancy. Detailed economic studies on the impact of DMD disease burden, costs, and healthcare resource utilization (HCRU) are limited.
objectiveTo compare healthcare costs, HCRU, and ambulatory status between a cohort of DMD patients and a matched cohort of patients without muscular dystrophies (non-MD). -
methodsA retrospective study was conducted using Merative MarketScan
resultsThe DMD and non-MD cohorts included 782 matched pairs. Patients with DMD had significantly higher mean unadjusted total healthcare costs (US$103,826.05 ± 309,335.71) per patient per year compared with patients with non-MD (US$3225.30 ± 13,865.14; p < 0.0001) per patient per year. The total healthcare cost was primarily driven by pharmacy and outpatient costs. The DMD cohort showed significantly higher HCRU than the non-MD cohort across physician offices, outpatient, emergency room, speech therapy, physical therapy, endocrinology, cardiology, orthopedic, pulmonology, and physical medicine visits. DMD patients with non-ambulatory status were older, medically progressed, and incurred higher costs than patients with ambulatory function.
conclusionsDMD imposes a substantial cost and healthcare resource burden on patients and the healthcare system. The results suggest a high unmet need that requires the development of novel therapies to treat DMD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.